Credit Suisse Bullish On Sarepta Therapeutics Inc

Analysts at Credit Suisse initiated coverage on Sarepta Therapeutics Inc SRPT with a Buy rating and $36 price target.

Analysts believe that Sarepta will achieve accelerated approval for eteplirsen within 12 to 18 months: "We recommend investors accumulate SRPT ahead of the expected spring FDA Advisory Committee meeting."

Other catalysts include, "(1) NDA acceptance in Q1:15, (2) 168-week data from ongoing Phase IIb in Q1:15, (3) FDA panel meeting in spring 2015, and (4) potential approval in YE:15/H1:16. Updates on manufacturing, FDA meetings, and clinical plans for follow-on therapies could also be catalysts in Q4:14/2015."

Shares of Sarepta Therapeutics Inc recently traded at $21.49, up 4.2 percent in the premarket.